Stephen V Liu, Associate Professor of Medicine at Georgetown University, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, shared a post on X:
“ELCC25 program includes OS updates from MARIPOSA and LAURA in EGFR NSCLC, adagrasib + pembrolizumab in KRAS G12C, and final analysis from KEYNOTE 799 of pembrolizumab + chemoradiation in stage III NSCLC.
Educational program highlights include AI session with Dr. Arsela Prelaj.”
